Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
55.13
-1.37 (-2.42%)
At close: Oct 31, 2025, 4:00 PM EDT
56.19
+1.06 (1.92%)
After-hours: Oct 31, 2025, 6:20 PM EDT
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $165.45M in the quarter ending June 30, 2025, a decrease of -1.71%. This brings the company's revenue in the last twelve months to $665.13M, up 5.55% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm)
$665.13M
Revenue Growth
+5.55%
P/S Ratio
4.61
Revenue / Employee
$986,832
Employees
674
Market Cap
3.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
| Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
| Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
| Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
| Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
SUPN News
- 11 days ago - Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 - GlobeNewsWire
- 6 weeks ago - Supernus Pharmaceuticals: Heading In The Right Direction - Seeking Alpha
- 2 months ago - Supernus Pharmaceuticals to Participate in September Investor Conferences - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Supernus Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - GlobeNewsWire